Related Experiment Video
Updated: Jul 26, 2026
11:03
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
Randomized controlled phase II trial of glatiramer acetate in ALS
P H Gordon1, C Doorish, J Montes
1Department of Neurology, Columbia University, NY, USA. phg8@columbia.edu
Neurology
|April 12, 2006
Summary
Glatiramer acetate showed a good safety profile and boosted immune responses in patients with Amyotrophic Lateral Sclerosis (ALS). These findings support further research into glatiramer acetate for ALS treatment.
Area of Science:
- Neuroscience
- Immunology
- Clinical Trials
Background:
- Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
- Glatiramer acetate is an immunomodulatory drug approved for multiple sclerosis.
Purpose of the Study:
- To evaluate the safety and immunological effects of glatiramer acetate in patients with ALS.
- To explore potential therapeutic benefits of glatiramer acetate in ALS.
Main Methods:
- A randomized controlled trial was conducted with 20 ALS patients receiving glatiramer acetate.
- Patients were assigned to daily or biweekly injection schedules.
- Ten control patients from a concurrent trial were included for comparison.
- Adverse events and immune responses, specifically lymphocyte proliferation, were monitored.
Main Results:
- Injection site reactions were the most frequent adverse event (p = 0.01).
- Glatiramer acetate treatment led to enhanced lymphocyte proliferation in treated patients (p = 0.02).
- The drug was generally well-tolerated, with no other common adverse events reported.
Conclusions:
- Glatiramer acetate demonstrates a favorable safety profile in ALS patients.
- The observed immune modulation suggests a potential therapeutic mechanism for glatiramer acetate in ALS.
- Larger clinical trials are warranted to determine optimal dosing and efficacy for ALS treatment.
